CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 7 enrolled
Drug / intervention
MagPro X100 by MagVenturedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03404609
NCT03404609N/ACompleted
CompareCT.gov

Rapid Non-Invasive Brain Stimulation for OCD (oTMS)

Stanford University·interventional·Posted Jan 19, 2018·Updated May 14, 2021

In Brief

A clinical study evaluating MagPro X100 by MagVenture for OCD. Completed, enrolled 7 participants across 1 site.

Detailed Summary

The purpose of this study is to understand how cortical stimulation affects Obsessive-Compulsive Disorder (OCD) symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOCD
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJan 19, 2018
Enrollment StartAug 25, 2018
Primary CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.5 years ago

Interventions

MagPro X100 by MagVenturedevice

Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.